Drug protocols for ovulation induction. A

Slides:



Advertisements
Similar presentations
Pituitary Gland FSH Primordial follicles Growing follicles LH.
Advertisements

Ovulation and Menstruation. Function of Menstrual Cycle Uterine walls thickens with rich blood supply in preparation for a fertilized egg If fertilization.
By the end of this lecture you will be able to: Recall how ovulation occurs and specify its hormonal regulation Recognize causes and types of female infertility.
ART Assisted reproductive technology Dithawut Khrutmuang MD.
The Hormones GnRH = gonadotropin-releasing hormone FSH = Folicle-stimulating hormone LH = Luteinizing hormone Testosterone Estrogen Progesterone.
Dr. Milton Leong Director
Accelerated Biology.  Some important vocabulary  Follicle – a cluster of cells that surrounds an immature egg and provides it with nutrients (where.
Agonist vs Antagonist Dr. Milton Leong.
A review on the luteal phase P Devroey MD PhD Centre for Reproductive Medicine Dutch-speaking Brussels Free University Brussels - Belgium.
Human Reproductive Systems Chapter 50, section 3 only.
Female Reproductive Cycle
Hormones synchronize ovarian and menstrual cycles
Female Reproductive Cycle
Chapter 9. THE HUMAN MENSTRUAL CYCLE Reid L. Norman, PhD Professor, Pharmacology and Neuroscience, TTUHSC.
That time of month UTERINE CYCLE Anne Fong BIO 260 M/WTonini.
Uterine (Menstrual) Cycle
Chapter 46.4 and 46.5 Animal Reproduction.
Reproductive System-L3
Female Reproductive System
Menotropins Drugbank ID : DB00032
A. Cervical cytology collection devices: (1) Plastic spatula
Schematic diagram of idealized regimens using exogenous gonadotropins for fertility induction. A. Step-up regimen for ovulation induction. After menses,
Menstrual Cycle and Fertilization
How IVF Protocols Work to Enhance the Success of IVF: Agonist vs Antagonist Dr Dimitrios Dovas MD Newlife IVF Greece.
The Reproductive System
Drugs In OVULATION INDUCTION.
Drug protocols for ovulation induction. A
Drug protocols for ovulation induction. A
The common denominator is development of a self-perpetuating noncyclic hormonal pattern. Source: Polycystic Ovarian Syndrome and Hyperandrogenism, Williams.
Unit B: Reproduction and Development
Use of GnRH antagonists for IVF
Computed tomographic (CT) images in the axial plane of a 61-year-old woman with endometrial cancer. A. Massively enlarged and inhomogeneous uterus (arrows)
Source: Chapter 23. Urinary Incontinence, Williams Gynecology, 2e
B. Major regulatory effects of ovarian steroids on hypothalamic-pituitary function. Estrogen decreases the amount of follicle-stimulating hormone (FSH)
Peritoneal incision overlying the sacrum.
Diagnostic algorithm to evaluate mastalgia
The Menstrual Cycle Biology 12.
Changes in the ovarian follicle, endometrial thickness, and serum hormone levels during a 28-day menstrual cycle. P, progesterone; E2, estradiol; LH, luteinizing.
Cervical pregnancy. A. Transvaginal sonography, sagittal view of a cervical pregnancy. Sonographic findings with cervical pregnancy may include: (1) an.
Various combined oral contraceptive (COC) pills. A. Extended-use COCs
به نام خدا Ovarian hyperstimulation syndrome
Intrauterine devices. The coronal planes of 3-dimensional sonography best depict the type and positioning of the Copper T 380A IUD (ParaGard) (A) and levonorgestrel-containing.
Hypothalamus Produces and releases Gonadotropin Releasing Hormone (GnRH) Stimulates the Anterior Pituitary Gland to produce and release Follicle Stimulating.
Intrauterine devices (IUDs)
COCs = combination oral contraceptive pills; GnRH = gonadotropin-releasing hormone; IUI = intrauterine insemination; NSAIDs = nonsteroidal antiinflammatory.
Intrauterine insemination (IUI)
Drawing illustrates the steps of oocyte development and corresponding follicular maturation. In the fetal period, once the primordial germ cells arrive.
The common denominator is development of a self-perpetuating noncyclic hormonal pattern. Source: Chapter 17. Polycystic Ovarian Syndrome and Hyperandrogenism,
within a Pfannenstiel incision scar. A
Da Vinci Surgical System. A. Operator console. B
Types of vulvectomy used in the treatment of vulvar cancer. A
Both a reproductive organ, and an endocrine gland
Chapter 17 Female Reproduction.
Menstruation IF fertilization does NOT take place
Recap questions chapter 8b
Learning Intentions Describe the sequence of events in the ovarian cycle, with reference to the follicular phase, ovulation, and luteal phase. Describe.
A reproductive organ, and an endocrine gland
Reproductive Hormones
Chorionic Gonadotropin (Human)
Organismal Development Part 4
Both a reproductive organ, and an endocrine gland
Menstrual Cycle.
1. FSH: Follicle-stimulating hormone; and LH: luteinizing hormone
A Chemical Signal Balancing Act
Regulation of the Reproductive System
Organismal Development Part 4
Lower levels of inhibin A and pro-αC during the luteal phase after triggering oocyte maturation with a gonadotropin-releasing hormone agonist versus human.
Introduction QUICK START: Controlled Ovarian Hyperstimulation Cycle.
QUICK START: Introduction
Introduction QUICK START: Controlled Ovarian Hyperstimulation Cycle.
Presentation transcript:

Drug protocols for ovulation induction. A Drug protocols for ovulation induction. A. Downregulation of gonadotropin-releasing hormone (GnRH) agonist protocol. This is also known as the long protocol. In this diagram, the long protocol is combined with combination oral contraceptive (COC) pill pretreatment. With the long protocol, GnRH agonists are begun typically 7 days prior to gonadotropins. GnRH agonists suppress endogenous pituitary release of gonadotropins. This minimizes the risk of a premature luteinizing hormone (LH) surge and thus premature ovulation. During all protocols, serial serum estrogen levels and sonographic surveillance of follicular development accompany gonadotropin administration. Human chorionic gonadotropin (hCG) is administered to trigger ovulation when sonography shows three or more follicles measuring at least 17 mm. Eggs are retrieved 36 hours later. Embryos are transfer back to the uterus 3–5 days following retrieval. Progesterone supplementation, with either vaginal preparations or intramuscular injection, follows during the luteal phase to support the endometrium. The goal of COC pretreatment is to prevent ovarian cyst formation. One of the major drawbacks of GnRH agonist therapy is the induction of initial transient gonadotropin release or flare, which may lead to ovarian cyst formation. Functional ovarian cysts can prolong the duration of pituitary suppression required prior to gonadotropin initiation and may also exert a detrimental effect on follicular development because of their steroid production. Moreover, COC pretreatment may improve induction results by providing an entire cohort of follicles synchronized at the same developmental stage that will reach maturity at the same time once stimulated by gonadotropins. B. GnRH flare protocol. This is also known as the short protocol. GnRH agonists initially bind gonadotropes and stimulate follicle-stimulating hormone (FSH) and LH release. This initial flare of gonadotropes stimulates follicular development. Following this initial surge of gonadotropins, the GnRH agonist causes receptor downregulation and an ultimately hypogonadotropic state. Gonadotropin injections begin 2 days later to continue follicular growth. As with the long protocol, continued GnRH agonist therapy prevents premature ovulation. C. GnRH antagonist protocol. As with GnRH agonists, these agents are combined with gonadotropins to prevent premature LH surge and ovulation. This protocol attempts to minimize risk of ovarian hyperstimulation syndrome (OHSS) and GnRH side effects, such as hot flashes, headaches, bleeding, and mood changes. Source: Treatment of the Infertile Couple, Williams Gynecology, 3e Citation: Hoffman BL, Schorge JO, Bradshaw KD, Halvorson LM, Schaffer JI, Corton MM. Williams Gynecology, 3e; 2016 Available at: http://obgyn.mhmedical.com/DownloadImage.aspx?image=/data/books/1758/p9780071849081-ch020_f002b.png&sec=118170633&BookID=1758&ChapterSecID=118170583&imagename= Accessed: January 02, 2018 Copyright © 2018 McGraw-Hill Education. All rights reserved